AMD Clinical Trials Lag in Adopting Standardized Patient Outcomes

Are AMD Trials Meeting Standardization Goals?

Standardized outcomes in macular degeneration trials show minimal adoption despite formal guidance, according to a new analysis of 159 clinical trials. Researchers found no significant increase in the use of recommended core outcome measures following the publication of standardized guidelines in 2016, with only visual acuity consistently reported across studies.

The cross-sectional study, conducted by researchers who analyzed ClinicalTrials.gov data spanning over a decade, reveals significant gaps in outcome standardization that could impact evidence synthesis and drug development for age-related macular degeneration (AMD). The research team employed an interrupted time series analysis to track changes in outcome reporting before and after the publication of the International Consortium for Health Outcomes Measurement (ICHOM) AMD Standard Set, which recommends seven standardized outcomes for consistent measurement. Their findings showed the mean percentage of core outcome completion increased by only 0.24% per month before publication and 0.07% per month after publication, indicating no meaningful change following the guidance's release. While visual acuity was measured in 87.4% of trials, other critical outcomes such as mobility and independence (18.9%), emotional well-being (20.8%), and reading ability (20.8%) were rarely assessed. The study's authors noted that among their sample, 83% of interventions involved intravitreal anti-VEGF treatments, with over 80% of trials receiving industry funding. "Our results demonstrate that the uptake of COS outcomes in MD clinical trials was inconsistent and that the release of the COS for MD has not significantly affected the measured outcomes in registered clinical trials," the researchers stated in their report. They pointed to trialists' potential lack of awareness, disagreement with standardized outcomes, and inadequate resources as barriers to implementation.

Can Regulatory Endorsement Transform Outcome Reporting?

This pattern diverges from experiences in other therapeutic areas like rheumatoid arthritis, where core outcome adoption doubled following endorsement by regulatory agencies including the FDA and European Medicines Agency. The authors propose that regulatory endorsement may be a crucial factor driving outcome selection in industry-sponsored trials. "Many of these clinical trials are being funded by drug companies that are seeking approval to commercialize their drugs, which has been shown to make trialists more likely to measure the outcomes endorsed by the regulatory agencies that grant the sought approval," they noted. Currently, the FDA has only an unofficial draft guidance for wet AMD that explicitly endorses distance visual acuity measurement, which aligns with the finding that visual acuity was the most commonly measured outcome. The researchers suggest that COS developers should actively seek regulatory agency endorsement to improve adoption rates, potentially by participating in regulatory workshops or providing feedback on industry guidance documents. This recommendation comes as pharmaceutical companies developing new AMD therapies continue to focus on visual acuity as their primary endpoint while potentially missing other patient-relevant outcomes.

The implications extend beyond academic interest, potentially affecting how new treatments are evaluated and marketed. Without standardized outcome measures, comparing efficacy across different trials and therapies becomes challenging, potentially complicating regulatory decisions and health technology assessments. For pharmaceutical companies developing next-generation AMD therapies that aim to differentiate from established anti-VEGF treatments, these findings suggest an opportunity to incorporate broader outcome measures that might better demonstrate value to patients, payers, and regulators. The study authors recommend further research analyzing the relationship between regulatory agency recommendations and clinical trial outcome selection, which could provide valuable insights for drug developers navigating the complex landscape of endpoint selection in ophthalmology trials.

Are Broader Outcome Measures the Future of AMD Therapies?

The research methodology included rigorous pre-registered protocols with predefined inclusion criteria and analysis methods. The team screened 364 phase III/IV trials from ClinicalTrials.gov, ultimately including 159 trials in their analysis after excluding studies that weren't exclusively focused on macular degeneration. Most trials occurred in 2014 (13.8%), with a median enrollment of 205 participants and a median trial duration of 31 months. The researchers acknowledged some limitations, noting that their reliance on ClinicalTrials.gov might underrepresent studies registered in non-US registries, particularly European AMD trials. Additionally, their extraction method focused on the "Outcome Measures" field may have underestimated the reporting of treatment complications if these were recorded elsewhere in the registry.

Industry Context: This study highlights a persistent challenge in clinical research standardization that extends beyond ophthalmology. As pharmaceutical companies increasingly focus on patient-centered outcomes and real-world evidence, the disconnect between recommended core outcomes and actual trial measurements represents a potential barrier to demonstrating comprehensive treatment benefits. The finding that regulatory preferences may drive outcome selection more strongly than consensus guidelines parallels similar patterns in other therapeutic areas, suggesting that strategic alignment with both regulatory requirements and patient-relevant outcomes will be essential for successful drug development programs. For investors and industry stakeholders, this research underscores the importance of monitoring evolving regulatory guidance in ophthalmic indications, as these may ultimately shape trial design and evidence generation more powerfully than academic consensus efforts.

Summary

A comprehensive analysis of 159 clinical trials for age-related macular degeneration reveals that standardized outcome measures recommended by the International Consortium for Health Outcomes Measurement have seen minimal adoption since their publication in 2016. While visual acuity was measured in 87.4% of trials, other patient-relevant outcomes such as emotional well-being, reading ability, and mobility were assessed in fewer than 21% of studies. The research indicates that outcome reporting improved by only 0.24% monthly before the guidelines and 0.07% monthly afterward, suggesting no meaningful impact from the standardization effort. The study attributes this pattern to trialists' lack of awareness, resource limitations, and particularly the absence of regulatory endorsement, contrasting with successful adoption in rheumatoid arthritis trials where FDA and European Medicines Agency endorsement doubled core outcome use. Currently, the FDA has only unofficial draft guidance endorsing distance visual acuity for wet AMD, which aligns with its predominant measurement in trials. With over 80% of the analyzed trials receiving industry funding and 83% testing anti-VEGF treatments, the findings suggest pharmaceutical companies focus primarily on regulatory requirements rather than comprehensive patient outcomes. The researchers recommend that core outcome developers seek formal regulatory endorsement and that drug developers incorporate broader outcome measures to better demonstrate treatment value, particularly as next-generation AMD therapies aim to differentiate from established treatments.